Target Name: CD8A
NCBI ID: G925
Review Report on CD8A Target / Biomarker Content of Review Report on CD8A Target / Biomarker
CD8A
Other Name(s): T-cell surface glycoprotein CD8 alpha chain | CD8A_HUMAN | CD8a | CD8A variant 1 | Leu2 | CD8 antigen, alpha polypeptide (p32) | T-cell surface glycoprotein CD8 alpha chain (isoform 1) | T cell co-receptor | T-lymphocyte differentiation antigen T8/Leu-2 | CD8a molecule | Leu2 T-lymphocyte antigen | CD8 antigen alpha polypeptide (isoform 1) | p32 | T-cell antigen Leu2 | CD8 | CD8a molecule, transcript variant 1 | OKT8 T-cell antigen | MAL | T8 T-cell antigen

CD8A as a Potential Drug Target and Biomarker for T-cell-mediated Diseases

CD8+ T cells are a crucial immune cell involved in fighting off infections and diseases. They are known for their ability to recognize and destroy infected or abnormal cells, making them a promising target for cancer and other diseases. The T-cell surface glycoprotein CD8 alpha chain is a key molecule on these cells, and its functions are still being fully understood. In this article, we will explore CD8A as a drug target and biomarker for T-cell-mediated diseases.

CD8A Structure and Function

CD8A is a glycoprotein that is expressed in the T-cells. It is one of the five known subunits of the T-cell receptor (TCR), which is a protein that plays a critical role in cell-mediated immunity. CD8A is a 22-kDa protein that consists of two heavy chains and two light chains. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region.

CD8A functions as a receptor for antigens. It is specifically expressed in T-cells and serves as a receptor for the antigens that the T-cells recognize and respond to. CD8A recognizes specific antigens through its extracellular domain, which consists of a single amino acid residue (Y) at its C-terminus. This specificity is critical for T-cell activation and subsequent immune responses.

CD8A is also involved in regulating T-cell responses to infections and cancer. It has been shown to regulate the activation and proliferation of T-cells, as well as their ability to recognize and destroy infected or abnormal cells.

CD8A as a Drug Target

CD8A has been identified as a potential drug target for cancer and other diseases due to its involvement in T-cell responses to infections and cancer. Several studies have shown that inhibiting CD8A can lead to a reduction in cancer cell proliferation and survival.

One of the main reasons for the potential of CD8A as a drug target is its role in T-cell responses to cancer. Many cancer cells are able to evade the immune system by inhibiting T-cell responses. By inhibiting CD8A, researchers have found that they can increase the immune response against cancer cells, leading to a greater ability to fight off these diseases.

Another potential mechanism by which CD8A may be used as a drug target is its role in regulating T-cell responses to infections. Many infections, including HIV, are able to replicate and cause disease by infecting and modifying T-cells. By inhibiting CD8A, researchers have found that they can reduce the ability of infected T-cells to survive and replicate, leading to a reduction in the severity of these infections.

CD8A as a Biomarker

CD8A has also been shown to be a potential biomarker for T-cell-mediated diseases. Its functions as a receptor for antigens and its role in regulating T-cell responses to infections make it an attractive marker for use in diagnostic tests.

One of the main applications of CD8A as a biomarker is its ability to be used as a marker for cancer. Many cancer cells have the ability to express CD8A, and research has shown that inhibiting CD8A can lead to a reduction in cancer cell proliferation and survival. This makes CD8A an attractive marker for use in cancer diagnostic tests.

Another potential application of CD8A as a biomarker is its ability to be used as a marker for infectious diseases. Many infectious diseases, including HIV, are able to infect and modify T-cells. By

Protein Name: CD8a Molecule

Functions: Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. The antigens presented by class I peptides are derived from cytosolic proteins while class II derived from extracellular proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. LCK then initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of cytotoxic T-lymphocytes (CTLs). This mechanism enables CTLs to recognize and eliminate infected cells and tumor cells. In NK-cells, the presence of CD8A homodimers at the cell surface provides a survival mechanism allowing conjugation and lysis of multiple target cells. CD8A homodimer molecules also promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells

The "CD8A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD8A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14